

## Marketing of oral artemisinin-based monotherapy medicines at country level

(Last updated on 24 October 2017)

### **National health authorities taking regulatory measures against the marketing of oral artemisinin-based monotherapies (oAMTs)**

**Of the 78 national health authorities which need  
artemisinin-based combination therapies (ACTs),  
73 do not authorize the marketing of oAMTs.**

**5 national health authorities  
have yet to withdraw their respective  
marketing authorization for oAMTs.**

**22 national health authorities**  
have never registered oAMTs

**51 national health authorities**  
have taken regulatory measures to withdraw  
the marketing authorization of oAMTs

**5 national health authorities**  
still allow the marketing of oAMTs  
for the treatment of uncomplicated malaria

Afghanistan  
Botswana  
Brazil  
Djibouti  
Ecuador  
Eritrea  
Ethiopia  
Indonesia  
Iran  
Malaysia  
Nepal  
Peru  
Philippines  
Saudi Arabia  
South Africa  
Sri Lanka  
Suriname  
Tajikistan  
Timor Leste  
Vanuatu  
Venezuela  
Zimbabwe

Bangladesh  
Benin  
Bhutan  
Bolivia  
Burkina Faso  
Burundi  
Cambodia  
Cameroon  
Central African Republic  
Chad  
China  
Colombia  
Comoros  
Congo  
Côte d'Ivoire  
Democratic Republic of Congo  
Equatorial Guinea  
Gabon  
Ghana  
Guinea  
Guinea-Bissau  
Guyana  
India  
Kenya  
Lao People's Democratic Republic  
Liberia  
Madagascar  
Malawi  
Mali  
Mauritania  
Mozambique  
Myanmar  
Namibia  
Niger  
Nigeria  
Pakistan  
Papua New Guinea  
Rwanda  
Sao Tome Principe  
Senegal  
Sierra Leone  
Solomon Islands  
Sudan  
Tanzania  
Thailand  
Toqo  
Uganda  
Viet Nam  
Yemen  
Zambia  
Zanzibar (United Republic of Tanzania)

Angola  
Cape Verde  
Gambia  
Somalia  
Swaziland